nodes	percent_of_prediction	percent_of_DWPC	metapath
Phenylpropanolamine—L-Phenylalanine—Melphalan—hematologic cancer	0.241	1	CrCrCtD
Phenylpropanolamine—CYP1A2—Anagrelide—hematologic cancer	0.0799	0.217	CbGbCtD
Phenylpropanolamine—CYP1A2—Carmustine—hematologic cancer	0.042	0.114	CbGbCtD
Phenylpropanolamine—CYP1A2—Methoxsalen—hematologic cancer	0.0357	0.097	CbGbCtD
Phenylpropanolamine—CYP1A2—Bortezomib—hematologic cancer	0.0339	0.0922	CbGbCtD
Phenylpropanolamine—CYP1A2—Daunorubicin—hematologic cancer	0.0325	0.0882	CbGbCtD
Phenylpropanolamine—CYP1A2—Alitretinoin—hematologic cancer	0.0318	0.0864	CbGbCtD
Phenylpropanolamine—CYP1A2—Thalidomide—hematologic cancer	0.0296	0.0803	CbGbCtD
Phenylpropanolamine—CYP1A2—Dacarbazine—hematologic cancer	0.0254	0.0691	CbGbCtD
Phenylpropanolamine—CYP1A2—Imatinib—hematologic cancer	0.0249	0.0676	CbGbCtD
Phenylpropanolamine—CYP1A2—Dasatinib—hematologic cancer	0.02	0.0543	CbGbCtD
Phenylpropanolamine—CYP1A2—Etoposide—hematologic cancer	0.0124	0.0338	CbGbCtD
Phenylpropanolamine—Pseudoephedrine—IL2—hematologic cancer	0.000671	0.748	CrCbGaD
Phenylpropanolamine—SLC6A3—hematopoietic system—hematologic cancer	0.000609	0.0849	CbGeAlD
Phenylpropanolamine—ADRA1A—hematopoietic system—hematologic cancer	0.000457	0.0637	CbGeAlD
Phenylpropanolamine—MAOA—hematopoietic system—hematologic cancer	0.000453	0.0631	CbGeAlD
Phenylpropanolamine—CYP1A2—hematopoietic system—hematologic cancer	0.000378	0.0526	CbGeAlD
Phenylpropanolamine—SLC6A2—gonad—hematologic cancer	0.000374	0.0521	CbGeAlD
Phenylpropanolamine—SLC6A3—lung—hematologic cancer	0.000354	0.0493	CbGeAlD
Phenylpropanolamine—ADRA2A—hematopoietic system—hematologic cancer	0.000348	0.0484	CbGeAlD
Phenylpropanolamine—ADRB1—lung—hematologic cancer	0.000336	0.0468	CbGeAlD
Phenylpropanolamine—SLC6A3—testis—hematologic cancer	0.000334	0.0465	CbGeAlD
Phenylpropanolamine—ADRA1A—blood—hematologic cancer	0.000303	0.0422	CbGeAlD
Phenylpropanolamine—MAOA—blood—hematologic cancer	0.0003	0.0418	CbGeAlD
Phenylpropanolamine—SLC6A2—lung—hematologic cancer	0.000286	0.0398	CbGeAlD
Phenylpropanolamine—SLC6A2—testis—hematologic cancer	0.000269	0.0375	CbGeAlD
Phenylpropanolamine—ADRA2A—gonad—hematologic cancer	0.000264	0.0368	CbGeAlD
Phenylpropanolamine—MAOA—lung—hematologic cancer	0.000263	0.0366	CbGeAlD
Phenylpropanolamine—CYP1A2—blood—hematologic cancer	0.00025	0.0349	CbGeAlD
Phenylpropanolamine—MAOA—testis—hematologic cancer	0.000248	0.0346	CbGeAlD
Phenylpropanolamine—ADRA2A—blood—hematologic cancer	0.00023	0.0321	CbGeAlD
Phenylpropanolamine—Pseudoephedrine—TNF—hematologic cancer	0.000227	0.252	CrCbGaD
Phenylpropanolamine—Hypotension—Mitoxantrone—hematologic cancer	0.000221	0.000871	CcSEcCtD
Phenylpropanolamine—CYP1A2—lung—hematologic cancer	0.00022	0.0306	CbGeAlD
Phenylpropanolamine—Insomnia—Vincristine—hematologic cancer	0.000219	0.000866	CcSEcCtD
Phenylpropanolamine—Vomiting—Vinblastine—hematologic cancer	0.000219	0.000865	CcSEcCtD
Phenylpropanolamine—Nausea—Nilotinib—hematologic cancer	0.000218	0.000862	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Thalidomide—hematologic cancer	0.000218	0.00086	CcSEcCtD
Phenylpropanolamine—Constipation—Carmustine—hematologic cancer	0.000217	0.000858	CcSEcCtD
Phenylpropanolamine—Nausea—Imatinib—hematologic cancer	0.000217	0.000857	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Bortezomib—hematologic cancer	0.000216	0.000853	CcSEcCtD
Phenylpropanolamine—Constipation—Alitretinoin—hematologic cancer	0.000215	0.00085	CcSEcCtD
Phenylpropanolamine—Hypotension—Gemcitabine—hematologic cancer	0.000215	0.000849	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Bleomycin—hematologic cancer	0.000214	0.000846	CcSEcCtD
Phenylpropanolamine—Insomnia—Irinotecan—hematologic cancer	0.000213	0.000843	CcSEcCtD
Phenylpropanolamine—Nausea—Cladribine—hematologic cancer	0.000213	0.000843	CcSEcCtD
Phenylpropanolamine—Constipation—Ifosfamide—hematologic cancer	0.000213	0.00084	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Vinorelbine—hematologic cancer	0.000211	0.000833	CcSEcCtD
Phenylpropanolamine—Dizziness—Lenalidomide—hematologic cancer	0.000211	0.000832	CcSEcCtD
Phenylpropanolamine—Ataxia—Epirubicin—hematologic cancer	0.000211	0.000832	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Mitoxantrone—hematologic cancer	0.00021	0.000831	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Irinotecan—hematologic cancer	0.00021	0.000831	CcSEcCtD
Phenylpropanolamine—Somnolence—Mitoxantrone—hematologic cancer	0.00021	0.000829	CcSEcCtD
Phenylpropanolamine—Somnolence—Irinotecan—hematologic cancer	0.00021	0.000829	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Carmustine—hematologic cancer	0.000209	0.000826	CcSEcCtD
Phenylpropanolamine—Tachycardia—Cisplatin—hematologic cancer	0.000209	0.000826	CcSEcCtD
Phenylpropanolamine—Vomiting—Melphalan—hematologic cancer	0.000208	0.000823	CcSEcCtD
Phenylpropanolamine—Insomnia—Gemcitabine—hematologic cancer	0.000208	0.000821	CcSEcCtD
Phenylpropanolamine—Dizziness—Hydroxyurea—hematologic cancer	0.000208	0.00082	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Alitretinoin—hematologic cancer	0.000207	0.000819	CcSEcCtD
Phenylpropanolamine—Constipation—Vincristine—hematologic cancer	0.000207	0.000819	CcSEcCtD
Phenylpropanolamine—Rash—Melphalan—hematologic cancer	0.000207	0.000816	CcSEcCtD
Phenylpropanolamine—Dermatitis—Melphalan—hematologic cancer	0.000206	0.000815	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Gemcitabine—hematologic cancer	0.000205	0.00081	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Ifosfamide—hematologic cancer	0.000205	0.000809	CcSEcCtD
Phenylpropanolamine—Nausea—Vinblastine—hematologic cancer	0.000205	0.000808	CcSEcCtD
Phenylpropanolamine—Somnolence—Gemcitabine—hematologic cancer	0.000204	0.000807	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Betamethasone—hematologic cancer	0.000203	0.000803	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Dexamethasone—hematologic cancer	0.000203	0.000803	CcSEcCtD
Phenylpropanolamine—Vomiting—Lenalidomide—hematologic cancer	0.000203	0.0008	CcSEcCtD
Phenylpropanolamine—ADRA2A—lung—hematologic cancer	0.000202	0.0281	CbGeAlD
Phenylpropanolamine—Constipation—Mitoxantrone—hematologic cancer	0.000202	0.000797	CcSEcCtD
Phenylpropanolamine—Constipation—Irinotecan—hematologic cancer	0.000202	0.000797	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Thiotepa—hematologic cancer	0.000201	0.000795	CcSEcCtD
Phenylpropanolamine—Rash—Lenalidomide—hematologic cancer	0.000201	0.000793	CcSEcCtD
Phenylpropanolamine—Dermatitis—Lenalidomide—hematologic cancer	0.000201	0.000793	CcSEcCtD
Phenylpropanolamine—Hypotension—Cisplatin—hematologic cancer	0.0002	0.000791	CcSEcCtD
Phenylpropanolamine—Vomiting—Hydroxyurea—hematologic cancer	0.0002	0.000789	CcSEcCtD
Phenylpropanolamine—Rash—Hydroxyurea—hematologic cancer	0.000198	0.000782	CcSEcCtD
Phenylpropanolamine—Confusional state—Etoposide—hematologic cancer	0.000198	0.000782	CcSEcCtD
Phenylpropanolamine—Dermatitis—Hydroxyurea—hematologic cancer	0.000198	0.000781	CcSEcCtD
Phenylpropanolamine—Hallucination—Prednisone—hematologic cancer	0.000197	0.000778	CcSEcCtD
Phenylpropanolamine—Constipation—Gemcitabine—hematologic cancer	0.000197	0.000777	CcSEcCtD
Phenylpropanolamine—SLC6A2—lymph node—hematologic cancer	0.000195	0.0272	CbGeAlD
Phenylpropanolamine—Ataxia—Doxorubicin—hematologic cancer	0.000195	0.00077	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Thalidomide—hematologic cancer	0.000195	0.000769	CcSEcCtD
Phenylpropanolamine—Nausea—Melphalan—hematologic cancer	0.000195	0.000769	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Mitoxantrone—hematologic cancer	0.000194	0.000768	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Irinotecan—hematologic cancer	0.000194	0.000768	CcSEcCtD
Phenylpropanolamine—Dizziness—Bortezomib—hematologic cancer	0.000194	0.000766	CcSEcCtD
Phenylpropanolamine—Tachycardia—Etoposide—hematologic cancer	0.000192	0.000757	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Cisplatin—hematologic cancer	0.000191	0.000755	CcSEcCtD
Phenylpropanolamine—ADRA2A—testis—hematologic cancer	0.00019	0.0265	CbGeAlD
Phenylpropanolamine—Feeling abnormal—Gemcitabine—hematologic cancer	0.000189	0.000748	CcSEcCtD
Phenylpropanolamine—Dizziness—Vinorelbine—hematologic cancer	0.000189	0.000748	CcSEcCtD
Phenylpropanolamine—Nausea—Lenalidomide—hematologic cancer	0.000189	0.000747	CcSEcCtD
Phenylpropanolamine—Tachycardia—Prednisolone—hematologic cancer	0.000189	0.000747	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Carmustine—hematologic cancer	0.000187	0.000739	CcSEcCtD
Phenylpropanolamine—Nausea—Hydroxyurea—hematologic cancer	0.000187	0.000737	CcSEcCtD
Phenylpropanolamine—Vomiting—Bortezomib—hematologic cancer	0.000186	0.000736	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Alitretinoin—hematologic cancer	0.000185	0.000732	CcSEcCtD
Phenylpropanolamine—Vomiting—Bleomycin—hematologic cancer	0.000185	0.00073	CcSEcCtD
Phenylpropanolamine—Rash—Bortezomib—hematologic cancer	0.000185	0.00073	CcSEcCtD
Phenylpropanolamine—Dermatitis—Bortezomib—hematologic cancer	0.000185	0.000729	CcSEcCtD
Phenylpropanolamine—Drowsiness—Methotrexate—hematologic cancer	0.000184	0.000728	CcSEcCtD
Phenylpropanolamine—Flushing—Prednisone—hematologic cancer	0.000184	0.000726	CcSEcCtD
Phenylpropanolamine—Hypotension—Etoposide—hematologic cancer	0.000183	0.000725	CcSEcCtD
Phenylpropanolamine—Rash—Bleomycin—hematologic cancer	0.000183	0.000724	CcSEcCtD
Phenylpropanolamine—Dermatitis—Bleomycin—hematologic cancer	0.000183	0.000724	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Ifosfamide—hematologic cancer	0.000183	0.000723	CcSEcCtD
Phenylpropanolamine—Vomiting—Vinorelbine—hematologic cancer	0.000182	0.000719	CcSEcCtD
Phenylpropanolamine—Dizziness—Thiotepa—hematologic cancer	0.000181	0.000714	CcSEcCtD
Phenylpropanolamine—Rash—Vinorelbine—hematologic cancer	0.00018	0.000713	CcSEcCtD
Phenylpropanolamine—Dermatitis—Vinorelbine—hematologic cancer	0.00018	0.000712	CcSEcCtD
Phenylpropanolamine—MAOA—lymph node—hematologic cancer	0.00018	0.0251	CbGeAlD
Phenylpropanolamine—Hypersensitivity—Vincristine—hematologic cancer	0.000179	0.000705	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Prednisone—hematologic cancer	0.000177	0.000699	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Cisplatin—hematologic cancer	0.000177	0.000698	CcSEcCtD
Phenylpropanolamine—Insomnia—Prednisolone—hematologic cancer	0.000175	0.000692	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Etoposide—hematologic cancer	0.000175	0.000691	CcSEcCtD
Phenylpropanolamine—Dizziness—Thalidomide—hematologic cancer	0.000175	0.000691	CcSEcCtD
Phenylpropanolamine—Somnolence—Etoposide—hematologic cancer	0.000175	0.000689	CcSEcCtD
Phenylpropanolamine—Nausea—Bortezomib—hematologic cancer	0.000174	0.000688	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Mitoxantrone—hematologic cancer	0.000174	0.000687	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Irinotecan—hematologic cancer	0.000174	0.000687	CcSEcCtD
Phenylpropanolamine—Tachycardia—Triamcinolone—hematologic cancer	0.000174	0.000687	CcSEcCtD
Phenylpropanolamine—Vomiting—Thiotepa—hematologic cancer	0.000174	0.000686	CcSEcCtD
Phenylpropanolamine—Nausea—Bleomycin—hematologic cancer	0.000173	0.000682	CcSEcCtD
Phenylpropanolamine—Drowsiness—Epirubicin—hematologic cancer	0.000173	0.000682	CcSEcCtD
Phenylpropanolamine—Rash—Thiotepa—hematologic cancer	0.000172	0.000681	CcSEcCtD
Phenylpropanolamine—Dermatitis—Thiotepa—hematologic cancer	0.000172	0.00068	CcSEcCtD
Phenylpropanolamine—Nausea—Vinorelbine—hematologic cancer	0.00017	0.000671	CcSEcCtD
Phenylpropanolamine—Vomiting—Thalidomide—hematologic cancer	0.000168	0.000664	CcSEcCtD
Phenylpropanolamine—Anxiety—Dexamethasone—hematologic cancer	0.000168	0.000663	CcSEcCtD
Phenylpropanolamine—Anxiety—Betamethasone—hematologic cancer	0.000168	0.000663	CcSEcCtD
Phenylpropanolamine—Dizziness—Carmustine—hematologic cancer	0.000168	0.000663	CcSEcCtD
Phenylpropanolamine—Constipation—Etoposide—hematologic cancer	0.000168	0.000663	CcSEcCtD
Phenylpropanolamine—Rash—Thalidomide—hematologic cancer	0.000167	0.000658	CcSEcCtD
Phenylpropanolamine—Dermatitis—Thalidomide—hematologic cancer	0.000167	0.000658	CcSEcCtD
Phenylpropanolamine—Dizziness—Alitretinoin—hematologic cancer	0.000166	0.000657	CcSEcCtD
Phenylpropanolamine—Dizziness—Ifosfamide—hematologic cancer	0.000164	0.000649	CcSEcCtD
Phenylpropanolamine—Vision blurred—Prednisone—hematologic cancer	0.000162	0.000642	CcSEcCtD
Phenylpropanolamine—Nausea—Thiotepa—hematologic cancer	0.000162	0.000641	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Etoposide—hematologic cancer	0.000162	0.000639	CcSEcCtD
Phenylpropanolamine—Vomiting—Carmustine—hematologic cancer	0.000161	0.000638	CcSEcCtD
Phenylpropanolamine—Insomnia—Triamcinolone—hematologic cancer	0.000161	0.000636	CcSEcCtD
Phenylpropanolamine—Dizziness—Vincristine—hematologic cancer	0.00016	0.000633	CcSEcCtD
Phenylpropanolamine—Rash—Carmustine—hematologic cancer	0.00016	0.000632	CcSEcCtD
Phenylpropanolamine—Dermatitis—Carmustine—hematologic cancer	0.00016	0.000632	CcSEcCtD
Phenylpropanolamine—Vomiting—Alitretinoin—hematologic cancer	0.00016	0.000632	CcSEcCtD
Phenylpropanolamine—Drowsiness—Doxorubicin—hematologic cancer	0.00016	0.000631	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Prednisolone—hematologic cancer	0.00016	0.00063	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Triamcinolone—hematologic cancer	0.000159	0.000627	CcSEcCtD
Phenylpropanolamine—Rash—Alitretinoin—hematologic cancer	0.000159	0.000626	CcSEcCtD
Phenylpropanolamine—Agitation—Prednisone—hematologic cancer	0.000158	0.000626	CcSEcCtD
Phenylpropanolamine—Dermatitis—Alitretinoin—hematologic cancer	0.000158	0.000626	CcSEcCtD
Phenylpropanolamine—Vomiting—Ifosfamide—hematologic cancer	0.000158	0.000624	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Cisplatin—hematologic cancer	0.000158	0.000624	CcSEcCtD
Phenylpropanolamine—Tachycardia—Betamethasone—hematologic cancer	0.000158	0.000623	CcSEcCtD
Phenylpropanolamine—Tachycardia—Dexamethasone—hematologic cancer	0.000158	0.000623	CcSEcCtD
Phenylpropanolamine—Nausea—Thalidomide—hematologic cancer	0.000157	0.00062	CcSEcCtD
Phenylpropanolamine—Rash—Ifosfamide—hematologic cancer	0.000157	0.000619	CcSEcCtD
Phenylpropanolamine—Dermatitis—Ifosfamide—hematologic cancer	0.000157	0.000619	CcSEcCtD
Phenylpropanolamine—Dizziness—Irinotecan—hematologic cancer	0.000156	0.000617	CcSEcCtD
Phenylpropanolamine—Vomiting—Vincristine—hematologic cancer	0.000154	0.000609	CcSEcCtD
Phenylpropanolamine—Rash—Vincristine—hematologic cancer	0.000153	0.000604	CcSEcCtD
Phenylpropanolamine—Dermatitis—Vincristine—hematologic cancer	0.000153	0.000603	CcSEcCtD
Phenylpropanolamine—Hypotension—Dexamethasone—hematologic cancer	0.000151	0.000596	CcSEcCtD
Phenylpropanolamine—Hypotension—Betamethasone—hematologic cancer	0.000151	0.000596	CcSEcCtD
Phenylpropanolamine—Nausea—Carmustine—hematologic cancer	0.000151	0.000596	CcSEcCtD
Phenylpropanolamine—Vomiting—Irinotecan—hematologic cancer	0.00015	0.000593	CcSEcCtD
Phenylpropanolamine—Vomiting—Mitoxantrone—hematologic cancer	0.00015	0.000593	CcSEcCtD
Phenylpropanolamine—Nausea—Alitretinoin—hematologic cancer	0.000149	0.00059	CcSEcCtD
Phenylpropanolamine—Rash—Mitoxantrone—hematologic cancer	0.000149	0.000588	CcSEcCtD
Phenylpropanolamine—Rash—Irinotecan—hematologic cancer	0.000149	0.000588	CcSEcCtD
Phenylpropanolamine—Dermatitis—Mitoxantrone—hematologic cancer	0.000149	0.000587	CcSEcCtD
Phenylpropanolamine—Dermatitis—Irinotecan—hematologic cancer	0.000149	0.000587	CcSEcCtD
Phenylpropanolamine—Nausea—Ifosfamide—hematologic cancer	0.000148	0.000583	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Triamcinolone—hematologic cancer	0.000147	0.00058	CcSEcCtD
Phenylpropanolamine—Anxiety—Prednisone—hematologic cancer	0.000146	0.000578	CcSEcCtD
Phenylpropanolamine—Vomiting—Gemcitabine—hematologic cancer	0.000146	0.000577	CcSEcCtD
Phenylpropanolamine—Insomnia—Betamethasone—hematologic cancer	0.000146	0.000577	CcSEcCtD
Phenylpropanolamine—Insomnia—Dexamethasone—hematologic cancer	0.000146	0.000577	CcSEcCtD
Phenylpropanolamine—Rash—Gemcitabine—hematologic cancer	0.000145	0.000573	CcSEcCtD
Phenylpropanolamine—Dermatitis—Gemcitabine—hematologic cancer	0.000145	0.000572	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Etoposide—hematologic cancer	0.000145	0.000571	CcSEcCtD
Phenylpropanolamine—Nausea—Vincristine—hematologic cancer	0.000144	0.000569	CcSEcCtD
Phenylpropanolamine—Flushing—Epirubicin—hematologic cancer	0.000144	0.000568	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Prednisolone—hematologic cancer	0.000143	0.000564	CcSEcCtD
Phenylpropanolamine—Nausea—Mitoxantrone—hematologic cancer	0.00014	0.000554	CcSEcCtD
Phenylpropanolamine—Nausea—Irinotecan—hematologic cancer	0.00014	0.000554	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Epirubicin—hematologic cancer	0.000138	0.000547	CcSEcCtD
Phenylpropanolamine—ADRA2A—lymph node—hematologic cancer	0.000138	0.0192	CbGeAlD
Phenylpropanolamine—Tachycardia—Prednisone—hematologic cancer	0.000137	0.000542	CcSEcCtD
Phenylpropanolamine—Nausea—Gemcitabine—hematologic cancer	0.000137	0.000539	CcSEcCtD
Phenylpropanolamine—Vomiting—Cisplatin—hematologic cancer	0.000136	0.000538	CcSEcCtD
Phenylpropanolamine—Vision blurred—Methotrexate—hematologic cancer	0.000136	0.000536	CcSEcCtD
Phenylpropanolamine—Rash—Cisplatin—hematologic cancer	0.000135	0.000534	CcSEcCtD
Phenylpropanolamine—Dermatitis—Cisplatin—hematologic cancer	0.000135	0.000533	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Betamethasone—hematologic cancer	0.000133	0.000526	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Dexamethasone—hematologic cancer	0.000133	0.000526	CcSEcCtD
Phenylpropanolamine—Flushing—Doxorubicin—hematologic cancer	0.000133	0.000525	CcSEcCtD
Phenylpropanolamine—Tension—Epirubicin—hematologic cancer	0.000132	0.000523	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Triamcinolone—hematologic cancer	0.000131	0.000518	CcSEcCtD
Phenylpropanolamine—Nervousness—Epirubicin—hematologic cancer	0.000131	0.000517	CcSEcCtD
Phenylpropanolamine—Dizziness—Etoposide—hematologic cancer	0.00013	0.000513	CcSEcCtD
Phenylpropanolamine—Dizziness—Prednisolone—hematologic cancer	0.000128	0.000506	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Doxorubicin—hematologic cancer	0.000128	0.000506	CcSEcCtD
Phenylpropanolamine—Nausea—Cisplatin—hematologic cancer	0.000127	0.000503	CcSEcCtD
Phenylpropanolamine—Insomnia—Prednisone—hematologic cancer	0.000127	0.000503	CcSEcCtD
Phenylpropanolamine—Vision blurred—Epirubicin—hematologic cancer	0.000127	0.000502	CcSEcCtD
Phenylpropanolamine—Vomiting—Etoposide—hematologic cancer	0.000125	0.000493	CcSEcCtD
Phenylpropanolamine—Agitation—Epirubicin—hematologic cancer	0.000124	0.000489	CcSEcCtD
Phenylpropanolamine—Rash—Etoposide—hematologic cancer	0.000124	0.000489	CcSEcCtD
Phenylpropanolamine—Dermatitis—Etoposide—hematologic cancer	0.000124	0.000489	CcSEcCtD
Phenylpropanolamine—Tension—Doxorubicin—hematologic cancer	0.000122	0.000484	CcSEcCtD
Phenylpropanolamine—Rash—Prednisolone—hematologic cancer	0.000122	0.000482	CcSEcCtD
Phenylpropanolamine—Dermatitis—Prednisolone—hematologic cancer	0.000122	0.000482	CcSEcCtD
Phenylpropanolamine—Nervousness—Doxorubicin—hematologic cancer	0.000121	0.000479	CcSEcCtD
Phenylpropanolamine—Constipation—Prednisone—hematologic cancer	0.00012	0.000475	CcSEcCtD
Phenylpropanolamine—Confusional state—Methotrexate—hematologic cancer	0.000119	0.000468	CcSEcCtD
Phenylpropanolamine—Dizziness—Triamcinolone—hematologic cancer	0.000118	0.000465	CcSEcCtD
Phenylpropanolamine—Vision blurred—Doxorubicin—hematologic cancer	0.000118	0.000464	CcSEcCtD
Phenylpropanolamine—Nausea—Etoposide—hematologic cancer	0.000117	0.000461	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Prednisone—hematologic cancer	0.000116	0.000458	CcSEcCtD
Phenylpropanolamine—Nausea—Prednisolone—hematologic cancer	0.000115	0.000454	CcSEcCtD
Phenylpropanolamine—Agitation—Doxorubicin—hematologic cancer	0.000115	0.000453	CcSEcCtD
Phenylpropanolamine—Anxiety—Epirubicin—hematologic cancer	0.000114	0.000452	CcSEcCtD
Phenylpropanolamine—Vomiting—Triamcinolone—hematologic cancer	0.000113	0.000447	CcSEcCtD
Phenylpropanolamine—Rash—Triamcinolone—hematologic cancer	0.000112	0.000444	CcSEcCtD
Phenylpropanolamine—Dermatitis—Triamcinolone—hematologic cancer	0.000112	0.000443	CcSEcCtD
Phenylpropanolamine—Confusional state—Epirubicin—hematologic cancer	0.000111	0.000438	CcSEcCtD
Phenylpropanolamine—Hypotension—Methotrexate—hematologic cancer	0.00011	0.000434	CcSEcCtD
Phenylpropanolamine—Tachycardia—Epirubicin—hematologic cancer	0.000107	0.000424	CcSEcCtD
Phenylpropanolamine—Dizziness—Betamethasone—hematologic cancer	0.000107	0.000422	CcSEcCtD
Phenylpropanolamine—Dizziness—Dexamethasone—hematologic cancer	0.000107	0.000422	CcSEcCtD
Phenylpropanolamine—Insomnia—Methotrexate—hematologic cancer	0.000106	0.00042	CcSEcCtD
Phenylpropanolamine—Anxiety—Doxorubicin—hematologic cancer	0.000106	0.000418	CcSEcCtD
Phenylpropanolamine—Nausea—Triamcinolone—hematologic cancer	0.000106	0.000418	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Methotrexate—hematologic cancer	0.000105	0.000414	CcSEcCtD
Phenylpropanolamine—Somnolence—Methotrexate—hematologic cancer	0.000105	0.000413	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Prednisone—hematologic cancer	0.000104	0.00041	CcSEcCtD
Phenylpropanolamine—Hypotension—Epirubicin—hematologic cancer	0.000103	0.000406	CcSEcCtD
Phenylpropanolamine—Vomiting—Betamethasone—hematologic cancer	0.000103	0.000406	CcSEcCtD
Phenylpropanolamine—Vomiting—Dexamethasone—hematologic cancer	0.000103	0.000406	CcSEcCtD
Phenylpropanolamine—Confusional state—Doxorubicin—hematologic cancer	0.000103	0.000406	CcSEcCtD
Phenylpropanolamine—Rash—Betamethasone—hematologic cancer	0.000102	0.000402	CcSEcCtD
Phenylpropanolamine—Rash—Dexamethasone—hematologic cancer	0.000102	0.000402	CcSEcCtD
Phenylpropanolamine—Dermatitis—Betamethasone—hematologic cancer	0.000102	0.000402	CcSEcCtD
Phenylpropanolamine—Dermatitis—Dexamethasone—hematologic cancer	0.000102	0.000402	CcSEcCtD
Phenylpropanolamine—Insomnia—Epirubicin—hematologic cancer	9.95e-05	0.000393	CcSEcCtD
Phenylpropanolamine—Tachycardia—Doxorubicin—hematologic cancer	9.94e-05	0.000393	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Epirubicin—hematologic cancer	9.81e-05	0.000388	CcSEcCtD
Phenylpropanolamine—Somnolence—Epirubicin—hematologic cancer	9.78e-05	0.000386	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Methotrexate—hematologic cancer	9.69e-05	0.000383	CcSEcCtD
Phenylpropanolamine—Nausea—Dexamethasone—hematologic cancer	9.6e-05	0.000379	CcSEcCtD
Phenylpropanolamine—Nausea—Betamethasone—hematologic cancer	9.6e-05	0.000379	CcSEcCtD
Phenylpropanolamine—Hypotension—Doxorubicin—hematologic cancer	9.51e-05	0.000376	CcSEcCtD
Phenylpropanolamine—Constipation—Epirubicin—hematologic cancer	9.41e-05	0.000372	CcSEcCtD
Phenylpropanolamine—Dizziness—Prednisone—hematologic cancer	9.3e-05	0.000368	CcSEcCtD
Phenylpropanolamine—Insomnia—Doxorubicin—hematologic cancer	9.21e-05	0.000364	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Doxorubicin—hematologic cancer	9.08e-05	0.000359	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Epirubicin—hematologic cancer	9.07e-05	0.000358	CcSEcCtD
Phenylpropanolamine—Somnolence—Doxorubicin—hematologic cancer	9.05e-05	0.000358	CcSEcCtD
Phenylpropanolamine—Vomiting—Prednisone—hematologic cancer	8.95e-05	0.000353	CcSEcCtD
Phenylpropanolamine—Rash—Prednisone—hematologic cancer	8.87e-05	0.00035	CcSEcCtD
Phenylpropanolamine—Dermatitis—Prednisone—hematologic cancer	8.86e-05	0.00035	CcSEcCtD
Phenylpropanolamine—Constipation—Doxorubicin—hematologic cancer	8.71e-05	0.000344	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Methotrexate—hematologic cancer	8.66e-05	0.000342	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Doxorubicin—hematologic cancer	8.39e-05	0.000331	CcSEcCtD
Phenylpropanolamine—Nausea—Prednisone—hematologic cancer	8.36e-05	0.00033	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Epirubicin—hematologic cancer	8.11e-05	0.00032	CcSEcCtD
Phenylpropanolamine—Dizziness—Methotrexate—hematologic cancer	7.78e-05	0.000307	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Doxorubicin—hematologic cancer	7.5e-05	0.000296	CcSEcCtD
Phenylpropanolamine—Vomiting—Methotrexate—hematologic cancer	7.48e-05	0.000295	CcSEcCtD
Phenylpropanolamine—Rash—Methotrexate—hematologic cancer	7.41e-05	0.000293	CcSEcCtD
Phenylpropanolamine—Dermatitis—Methotrexate—hematologic cancer	7.41e-05	0.000293	CcSEcCtD
Phenylpropanolamine—Dizziness—Epirubicin—hematologic cancer	7.28e-05	0.000287	CcSEcCtD
Phenylpropanolamine—Vomiting—Epirubicin—hematologic cancer	7e-05	0.000276	CcSEcCtD
Phenylpropanolamine—Nausea—Methotrexate—hematologic cancer	6.98e-05	0.000276	CcSEcCtD
Phenylpropanolamine—Rash—Epirubicin—hematologic cancer	6.94e-05	0.000274	CcSEcCtD
Phenylpropanolamine—Dermatitis—Epirubicin—hematologic cancer	6.93e-05	0.000274	CcSEcCtD
Phenylpropanolamine—Dizziness—Doxorubicin—hematologic cancer	6.73e-05	0.000266	CcSEcCtD
Phenylpropanolamine—Nausea—Epirubicin—hematologic cancer	6.54e-05	0.000258	CcSEcCtD
Phenylpropanolamine—Vomiting—Doxorubicin—hematologic cancer	6.47e-05	0.000256	CcSEcCtD
Phenylpropanolamine—Rash—Doxorubicin—hematologic cancer	6.42e-05	0.000254	CcSEcCtD
Phenylpropanolamine—Dermatitis—Doxorubicin—hematologic cancer	6.41e-05	0.000253	CcSEcCtD
Phenylpropanolamine—Nausea—Doxorubicin—hematologic cancer	6.05e-05	0.000239	CcSEcCtD
Phenylpropanolamine—DRD1—Signaling by GPCR—PIK3CA—hematologic cancer	7.06e-06	5.43e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PIK3CD—hematologic cancer	7.05e-06	5.42e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MDM2—hematologic cancer	7.03e-06	5.4e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MAPK14—hematologic cancer	7e-06	5.38e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CD44—hematologic cancer	7e-06	5.38e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—NQO1—hematologic cancer	7e-06	5.38e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PDGFB—hematologic cancer	6.99e-06	5.37e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—PIK3CA—hematologic cancer	6.99e-06	5.37e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MAP2K1—hematologic cancer	6.95e-06	5.34e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—KRAS—hematologic cancer	6.91e-06	5.31e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PIK3CD—hematologic cancer	6.9e-06	5.31e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—ESR1—hematologic cancer	6.87e-06	5.28e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	6.85e-06	5.27e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PIK3CB—hematologic cancer	6.84e-06	5.26e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MTOR—hematologic cancer	6.84e-06	5.26e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—PIK3CA—hematologic cancer	6.84e-06	5.25e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TSC2—hematologic cancer	6.83e-06	5.25e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—EP300—hematologic cancer	6.82e-06	5.24e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—AKT1—hematologic cancer	6.79e-06	5.22e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—FN1—hematologic cancer	6.78e-06	5.22e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—KRAS—hematologic cancer	6.76e-06	5.19e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—FGF2—hematologic cancer	6.75e-06	5.19e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—BAD—hematologic cancer	6.7e-06	5.15e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—NFKBIA—hematologic cancer	6.7e-06	5.15e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—CREBBP—hematologic cancer	6.69e-06	5.14e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PIK3R1—hematologic cancer	6.66e-06	5.12e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—NOTCH1—hematologic cancer	6.64e-06	5.1e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CYCS—hematologic cancer	6.62e-06	5.09e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—FGF2—hematologic cancer	6.61e-06	5.08e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—HSP90AA1—hematologic cancer	6.58e-06	5.06e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—FGFR3—hematologic cancer	6.57e-06	5.05e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—HRAS—hematologic cancer	6.53e-06	5.02e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PIK3R1—hematologic cancer	6.52e-06	5.01e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MAPK14—hematologic cancer	6.51e-06	5e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CD80—hematologic cancer	6.5e-06	5e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PIK3CG—hematologic cancer	6.49e-06	4.99e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—KIT—hematologic cancer	6.49e-06	4.99e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—NRAS—hematologic cancer	6.49e-06	4.99e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—JAK2—hematologic cancer	6.47e-06	4.98e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CDKN1B—hematologic cancer	6.42e-06	4.93e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—ESR1—hematologic cancer	6.38e-06	4.91e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PTPN11—hematologic cancer	6.38e-06	4.9e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—AKT1—hematologic cancer	6.35e-06	4.88e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—PIK3CA—hematologic cancer	6.35e-06	4.88e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PIK3CD—hematologic cancer	6.34e-06	4.88e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—JAK2—hematologic cancer	6.33e-06	4.87e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MDM2—hematologic cancer	6.32e-06	4.86e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—FN1—hematologic cancer	6.3e-06	4.85e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CASP3—hematologic cancer	6.29e-06	4.84e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IL2—hematologic cancer	6.28e-06	4.83e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—ALB—hematologic cancer	6.26e-06	4.81e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—IL6—hematologic cancer	6.25e-06	4.8e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—BAD—hematologic cancer	6.23e-06	4.79e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NFKBIA—hematologic cancer	6.23e-06	4.79e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—MAPK3—hematologic cancer	6.22e-06	4.78e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—PIK3CA—hematologic cancer	6.21e-06	4.77e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MDM2—hematologic cancer	6.18e-06	4.75e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CREB1—hematologic cancer	6.18e-06	4.75e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NOTCH1—hematologic cancer	6.17e-06	4.74e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PIK3CB—hematologic cancer	6.15e-06	4.73e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MTOR—hematologic cancer	6.15e-06	4.73e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CCND1—hematologic cancer	6.12e-06	4.71e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—JUN—hematologic cancer	6.11e-06	4.7e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—BRAF—hematologic cancer	6.1e-06	4.69e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CCL2—hematologic cancer	6.05e-06	4.65e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CD80—hematologic cancer	6.04e-06	4.65e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PIK3CG—hematologic cancer	6.03e-06	4.64e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—KIT—hematologic cancer	6.03e-06	4.64e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—NRAS—hematologic cancer	6.03e-06	4.64e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IL6R—hematologic cancer	6.03e-06	4.64e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CREBBP—hematologic cancer	6.02e-06	4.63e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MTOR—hematologic cancer	6.02e-06	4.62e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PIK3CB—hematologic cancer	6.02e-06	4.62e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PIK3R1—hematologic cancer	5.99e-06	4.6e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PTPN11—hematologic cancer	5.93e-06	4.56e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CDKN1A—hematologic cancer	5.92e-06	4.55e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	5.92e-06	4.55e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PTEN—hematologic cancer	5.91e-06	4.54e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—HRAS—hematologic cancer	5.87e-06	4.51e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GSTP1—hematologic cancer	5.84e-06	4.49e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MAPK8—hematologic cancer	5.78e-06	4.44e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—MAPK3—hematologic cancer	5.78e-06	4.44e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CDKN1B—hematologic cancer	5.77e-06	4.44e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—AKT1—hematologic cancer	5.77e-06	4.43e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MAP2K1—hematologic cancer	5.75e-06	4.42e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—HRAS—hematologic cancer	5.74e-06	4.42e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CREB1—hematologic cancer	5.74e-06	4.41e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—AKT1—hematologic cancer	5.71e-06	4.39e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PIK3CD—hematologic cancer	5.71e-06	4.39e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—BRAF—hematologic cancer	5.67e-06	4.36e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CASP3—hematologic cancer	5.66e-06	4.35e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—PIK3CA—hematologic cancer	5.65e-06	4.35e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	5.65e-06	4.34e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IL2—hematologic cancer	5.65e-06	4.34e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CDKN1B—hematologic cancer	5.64e-06	4.34e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—EP300—hematologic cancer	5.64e-06	4.33e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—IL6—hematologic cancer	5.62e-06	4.32e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CCL2—hematologic cancer	5.62e-06	4.32e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IL6R—hematologic cancer	5.6e-06	4.31e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CREBBP—hematologic cancer	5.59e-06	4.3e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—KRAS—hematologic cancer	5.59e-06	4.3e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—AKT1—hematologic cancer	5.58e-06	4.29e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CASP3—hematologic cancer	5.53e-06	4.25e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PIK3CB—hematologic cancer	5.53e-06	4.25e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ABCB1—hematologic cancer	5.53e-06	4.25e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IL2—hematologic cancer	5.52e-06	4.25e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CCND1—hematologic cancer	5.51e-06	4.23e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—IL6—hematologic cancer	5.5e-06	4.23e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—JUN—hematologic cancer	5.49e-06	4.22e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—SRC—hematologic cancer	5.48e-06	4.21e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—FGF2—hematologic cancer	5.47e-06	4.2e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PIK3R1—hematologic cancer	5.39e-06	4.14e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CCND1—hematologic cancer	5.39e-06	4.14e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—JUN—hematologic cancer	5.37e-06	4.13e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GSTM1—hematologic cancer	5.36e-06	4.12e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—NCOR1—hematologic cancer	5.36e-06	4.12e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MAP2K1—hematologic cancer	5.34e-06	4.1e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—VEGFA—hematologic cancer	5.34e-06	4.1e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CDKN1A—hematologic cancer	5.33e-06	4.09e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PTEN—hematologic cancer	5.31e-06	4.08e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PIK3CD—hematologic cancer	5.3e-06	4.08e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—STAT3—hematologic cancer	5.29e-06	4.06e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—NRAS—hematologic cancer	5.27e-06	4.05e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—PIK3CA—hematologic cancer	5.25e-06	4.04e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—JAK2—hematologic cancer	5.24e-06	4.03e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CDKN1A—hematologic cancer	5.21e-06	4e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MAPK8—hematologic cancer	5.2e-06	4e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PTEN—hematologic cancer	5.2e-06	4e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—KRAS—hematologic cancer	5.19e-06	3.99e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—AKT1—hematologic cancer	5.18e-06	3.99e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—PIK3CA—hematologic cancer	5.13e-06	3.95e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MDM2—hematologic cancer	5.11e-06	3.93e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MAPK8—hematologic cancer	5.08e-06	3.91e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—FGF2—hematologic cancer	5.08e-06	3.9e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—AKT1—hematologic cancer	5.07e-06	3.9e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—EP300—hematologic cancer	5.07e-06	3.9e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MAPK3—hematologic cancer	5.05e-06	3.88e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—PIK3CA—hematologic cancer	5.04e-06	3.88e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PIK3R1—hematologic cancer	5.01e-06	3.85e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MTOR—hematologic cancer	4.98e-06	3.82e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PIK3CB—hematologic cancer	4.98e-06	3.82e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—EP300—hematologic cancer	4.96e-06	3.81e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—SRC—hematologic cancer	4.93e-06	3.79e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MYC—hematologic cancer	4.91e-06	3.78e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—TGFB1—hematologic cancer	4.9e-06	3.77e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—JAK2—hematologic cancer	4.87e-06	3.74e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—SRC—hematologic cancer	4.82e-06	3.71e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—VEGFA—hematologic cancer	4.8e-06	3.69e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PTEN—hematologic cancer	4.78e-06	3.67e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—PIK3CA—hematologic cancer	4.77e-06	3.67e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—STAT3—hematologic cancer	4.75e-06	3.65e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MDM2—hematologic cancer	4.75e-06	3.65e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—HRAS—hematologic cancer	4.75e-06	3.65e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—NRAS—hematologic cancer	4.74e-06	3.64e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—MTHFR—hematologic cancer	4.74e-06	3.64e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—VEGFA—hematologic cancer	4.69e-06	3.61e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CDKN1B—hematologic cancer	4.67e-06	3.59e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—STAT3—hematologic cancer	4.65e-06	3.57e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—NRAS—hematologic cancer	4.64e-06	3.57e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MTOR—hematologic cancer	4.62e-06	3.55e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PIK3CB—hematologic cancer	4.62e-06	3.55e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—AKT1—hematologic cancer	4.62e-06	3.55e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CASP3—hematologic cancer	4.58e-06	3.52e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IL2—hematologic cancer	4.57e-06	3.51e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—EP300—hematologic cancer	4.56e-06	3.5e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—IL6—hematologic cancer	4.55e-06	3.5e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MAPK3—hematologic cancer	4.54e-06	3.49e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—KRAS—hematologic cancer	4.54e-06	3.49e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CCND1—hematologic cancer	4.45e-06	3.42e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—JUN—hematologic cancer	4.44e-06	3.42e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MAPK3—hematologic cancer	4.44e-06	3.41e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MYC—hematologic cancer	4.42e-06	3.39e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—HRAS—hematologic cancer	4.41e-06	3.39e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TGFB1—hematologic cancer	4.4e-06	3.39e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CDKN1B—hematologic cancer	4.34e-06	3.34e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MYC—hematologic cancer	4.32e-06	3.32e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CDKN1A—hematologic cancer	4.31e-06	3.31e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TGFB1—hematologic cancer	4.31e-06	3.31e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PTEN—hematologic cancer	4.3e-06	3.31e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—AKT1—hematologic cancer	4.29e-06	3.3e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CASP3—hematologic cancer	4.25e-06	3.27e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IL2—hematologic cancer	4.25e-06	3.26e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—IL6—hematologic cancer	4.22e-06	3.25e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MAPK8—hematologic cancer	4.21e-06	3.23e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—AKT1—hematologic cancer	4.19e-06	3.22e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	4.18e-06	3.21e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PIK3CA—hematologic cancer	4.17e-06	3.21e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CCND1—hematologic cancer	4.14e-06	3.18e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—JUN—hematologic cancer	4.13e-06	3.17e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—AKT1—hematologic cancer	4.12e-06	3.17e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—EP300—hematologic cancer	4.1e-06	3.15e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—KRAS—hematologic cancer	4.08e-06	3.14e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—TP53—hematologic cancer	4.03e-06	3.1e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CDKN1A—hematologic cancer	4e-06	3.08e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PTEN—hematologic cancer	3.99e-06	3.07e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—KRAS—hematologic cancer	3.99e-06	3.07e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—SRC—hematologic cancer	3.99e-06	3.07e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PIK3CG—hematologic cancer	3.98e-06	3.06e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MAPK8—hematologic cancer	3.91e-06	3e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—AKT1—hematologic cancer	3.9e-06	3e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—VEGFA—hematologic cancer	3.88e-06	2.99e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—HRAS—hematologic cancer	3.86e-06	2.97e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—STAT3—hematologic cancer	3.85e-06	2.96e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—NRAS—hematologic cancer	3.84e-06	2.95e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—EP300—hematologic cancer	3.81e-06	2.93e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PIK3CA—hematologic cancer	3.75e-06	2.88e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—SRC—hematologic cancer	3.7e-06	2.85e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CREBBP—hematologic cancer	3.69e-06	2.84e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IL6—hematologic cancer	3.69e-06	2.84e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MAPK3—hematologic cancer	3.67e-06	2.82e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PIK3CA—hematologic cancer	3.67e-06	2.82e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TP53—hematologic cancer	3.63e-06	2.79e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—VEGFA—hematologic cancer	3.61e-06	2.77e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MYC—hematologic cancer	3.57e-06	2.75e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—STAT3—hematologic cancer	3.57e-06	2.75e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TGFB1—hematologic cancer	3.56e-06	2.74e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NRAS—hematologic cancer	3.56e-06	2.74e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TP53—hematologic cancer	3.55e-06	2.73e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PIK3CD—hematologic cancer	3.5e-06	2.69e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—HRAS—hematologic cancer	3.47e-06	2.67e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ALB—hematologic cancer	3.46e-06	2.66e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MAPK3—hematologic cancer	3.41e-06	2.62e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—AKT1—hematologic cancer	3.41e-06	2.62e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—HRAS—hematologic cancer	3.39e-06	2.61e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PIK3CA—hematologic cancer	3.37e-06	2.59e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MYC—hematologic cancer	3.32e-06	2.55e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IL6—hematologic cancer	3.32e-06	2.55e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TGFB1—hematologic cancer	3.31e-06	2.55e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PIK3R1—hematologic cancer	3.31e-06	2.54e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—KRAS—hematologic cancer	3.3e-06	2.54e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IL6—hematologic cancer	3.25e-06	2.5e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—KRAS—hematologic cancer	3.07e-06	2.36e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—AKT1—hematologic cancer	3.06e-06	2.35e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PIK3CB—hematologic cancer	3.05e-06	2.35e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PIK3CA—hematologic cancer	3.03e-06	2.33e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—AKT1—hematologic cancer	3e-06	2.3e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TP53—hematologic cancer	2.93e-06	2.26e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PIK3CA—hematologic cancer	2.82e-06	2.17e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—HRAS—hematologic cancer	2.81e-06	2.16e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—AKT1—hematologic cancer	2.75e-06	2.12e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TP53—hematologic cancer	2.73e-06	2.1e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IL6—hematologic cancer	2.69e-06	2.06e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PTEN—hematologic cancer	2.64e-06	2.03e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—HRAS—hematologic cancer	2.61e-06	2e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—EP300—hematologic cancer	2.52e-06	1.93e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IL6—hematologic cancer	2.5e-06	1.92e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—AKT1—hematologic cancer	2.48e-06	1.9e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—AKT1—hematologic cancer	2.3e-06	1.77e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PIK3CA—hematologic cancer	1.86e-06	1.43e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—AKT1—hematologic cancer	1.52e-06	1.17e-05	CbGpPWpGaD
